Loading patent…
AssigneeChiesi Farmaceutici S.p.A.
InventorsClive Arthur Arculus-Meanwell, Simona Skerjanec, Jayne Prats
Estimating the term…
Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising bivalirudin or a P2Y12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor, and optionally bivalirudin. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
A method of treating or reducing the incidence of an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising concurrently administering to the patient a pharmaceutical composition comprising only one active composition, wherein the only one active composition consists essentially of cangrelor and a pharmaceutically acceptable excipient comprising one or more of the group consisting of mannitol and sorbitol, wherein the only one active composition is lyophilized;
Dependencies are inferred from the claim text.